Alnylam Pharmaceuticals has signed a deal with medical device maker Medtronic to co-develop therapies for neurodegenerative disorders such as Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease, the companies said this week.
Under the arrangement, Alnylam would develop RNAi-based drugs to treat the various diseases, while Medtronic would develop medical devices to deliver the drugs to specific locations within the nervous system.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
